|
EP3718404A1
|
|
Use of methylnaltrexone to attenuate tumor progession
|
|
AU2015221520A1
|
|
Colonic purgative composition with soluble binding agent
|
|
WO2016014864A1
|
|
Hydroxy-(r),(r)-2,2'-bismethylnaltrexones and uses thereof
|
|
WO2015191686A1
|
|
Methods of administering methylnaltrexone
|
|
WO2015171493A1
|
|
Ibs microbiota and uses thereof
|
|
KR20170038810A
|
|
Methods for retreating irritable bowel syndrome (ibs)
|
|
WO2015073846A1
|
|
Method of treating ulcerative colitis
|
|
US2015132284A1
|
|
Method of treating ulcerative colitis
|
|
US2014349983A1
|
|
Method for treating ulcerative colitis
|
|
US2014349982A1
|
|
Methods of treating ulcerative colitis
|
|
CA2912712A1
|
|
Methods of using rifaximin in position emission tomography (pet) scans
|
|
AU2013270516A1
|
|
Rifaximin anti-rectal dysfunction preparation
|
|
AU2013228061A1
|
|
Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
|
|
AU2013315383A1
|
|
Methods of improving long-term survival and reducing hospitalization readmission rates for subjects suffering from hepatic encephalopathy
|
|
EP2894983A1
|
|
Methods of administering rifaximin for weight loss and treatment of obesity
|
|
CN104955457A
|
|
Methods of administering rifaximin without producing antibiotic resistance
|
|
MX2015002210A
|
|
Laxative compositions and methods for treating constipation and related gastrointestinal diseases and conditions.
|
|
AU2013202513A1
|
|
Polyethylene glycol colonic purgative composition
|
|
EP2928560A1
|
|
Methods and compositions for treating hiv-associated diarrhea
|
|
AU2012211460A1
|
|
Balsalazide formulations and manufacture and use thereof
|
